NCT00106834 – A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction and Maintenance Therapy in Patients With Moderate to Severe Plaque Psoriasis Posted on August 5, 2023 by tsuperadmin -
NCT00230529 – A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab (REMICADE) Induction Therapy in Patients With Plaque-type Psoriasis Posted on August 5, 2023 by tsuperadmin -
NCT02207231 – Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis Posted on August 5, 2023 by tsuperadmin -
NCT04021862 – A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis Posted on August 5, 2023 by tsuperadmin -
NCT00317538 – Open-label, Pilot Protocol of Patients with Rheumatoid Arthritis Who Switch to Infliximab after Incomplete Response to Etanercept Posted on August 5, 2023 by tsuperadmin -
NCT00816166 – Phase III Study of Pharos Vitesse Neurovascular Stent System Compared to Best Medical Therapy for the Treatment of Ischemic Disease Posted on August 5, 2023 by tsuperadmin -
NCT03090100 – A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis Posted on August 5, 2023 by tsuperadmin -
NCT00668837 – Open Label Extension to R076477-SCH-305 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia Posted on August 5, 2023 by tsuperadmin -
NCT03345342 – A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation Posted on August 5, 2023 by tsuperadmin -
NCT04019041 – A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa Posted on August 5, 2023 by tsuperadmin -
The YODA Project